Antisense oligonucleotides
Antisense oligonucleotides has been studied in 44 papers since 2017: none in people yet, 4 in animals, 2 in cells, 38 reviews; 36 in the past year. The research so far is in animals and cells. The newest paper, Nov 17, 2026: “Machine Learning-Guided Design of Peptide-Targeted CRISPR Vectors for Tissue-Specific Non-Coding RNA Knockdown”.
InterventionPreclinical
44 papers study it19 findingsUpdated
Research on it is growing 486% faster than aging research as a whole: 20 papers in the latest year counted
9 new papers in 30 daysSee all 43 papers on antisense oligonucleotides
At a glance
Antisense oligonucleotides extend lifespan in Hutchinson–Gilford progeria mouse models, a result independently reproduced in mice. In progeroid patient fibroblasts, L1 RNA depletion reduces epigenetic age and senescence-associated secretory phenotype gene expression. Most reported results involve authors at Altos Labs or Ionis Pharmaceuticals, and a paper declares ties to Ionis.
19 findings in 13 papers from 2017 to 2026, 4 of them since August 2026
The findings reach people, from one lab or study; independent labs found the same change in mice. 4 independent labs in 4 countries.
None of its findings points the other way.
- 4 independent labs in 4 countries
- Funders: National Cancer Institute and others
- 7 of 10 findings with company ties
- Animals4
- Cells2
What did studies of antisense oligonucleotides find?
14Studies of antisense oligonucleotides measured 14 outcomes; the most studied are lipoprotein (5 studies) and lifespan (2).
Lipoprotein
downin humans5−90%
5 studies
Lipoprotein
downin humans5−90%
Antisense oligonucleotides decrease lipoprotein in humans (Elevated Lp(a); ASO trials versus placebo) (−74 to −80 nmol/L).
“ASO trials demonstrated more modest reductions (−74 to −80 nmol/L) with greater variability.”
ReviewElevated Lp(a); ASO trials versus placebo
ESC Congress 2026 abstract
Antisense oligonucleotides decrease lipoprotein in humans (65% to >95%).
“RNA-targeted agents, comprising antisense oligonucleotides and small interfering RNAs, together with a first oral small-molecule inhibitor, lower Lp(a) by about 65% to more than 95%”
Review
Lipoprotein(a) in the statin era: from risk marker to therapeutic target
Frontiers in pharmacology
Antisense oligonucleotides decrease lipoprotein in humans (up to 90%).
“Novel therapies-including antisense oligonucleotides, siRNA therapeutics, CETP inhibitors, and experimental gene-editing approaches-show promising potential, reducing Lp(a) levels by up to 90%.”
Review
Lipoprotein(a) as a Cardiovascular Risk Factor: Clinical Significance and Therapeutic Perspectives
Biomedicines
Antisense oligonucleotides decrease lipoprotein in humans (Phase II trials).
“antisense oligonucleotides and small interfering RNAs) and a small molecule inhibitor of Lp(a) synthesis, demonstrated substantial and often durable Lp(a)-lowering effects in Phase II trials.”
ReviewPhase II trials
Lipoprotein(a)-lowering therapies: a promising future
European heart journal
Antisense oligonucleotides decrease lipoprotein in humans.
“Novel therapeutics, including antisense oligonucleotides, small interfering RNAs, and small molecular inhibitors, have shown promising Lp(a)-lowering effects”
Review
Journal of lipid and atherosclerosis
Lifespan
upin mice2
2 studies
Lifespan
upin mice2
Antisense oligonucleotides extend lifespan in mice (systemic delivery in a Hutchinson-Gilford progeria syndrome mouse model).
“systemic delivery of ASOs rescued the histophysiology of tissues and increased the life span of a Hutchinson-Gilford progeria syndrome mouse model”
Animalssystemic delivery in a Hutchinson-Gilford progeria syndrome mouse model
Science translational medicine
Antisense oligonucleotides extend lifespan in mice (mouse model of HGPS).
“Treatment with an optimized lead candidate resulted in extension of lifespan in a mouse model of HGPS.”
Animalsmouse model of HGPSoptimized lead candidate targeting the LMNA exon 12 junction
Nature medicine
Angiotensinogen
downin humans1
1 study
Angiotensinogen
downin humans1
Antisense oligonucleotides inhibit angiotensinogen in humans (hypertension).
“Antisense strategies have provided additional clinical validation of sustained angiotensinogen inhibition, although their antihypertensive efficacy has been less consistent.”
Reviewhypertension
Current cardiology reports
RNA splicing
upin reviews1
1 study
RNA splicing
upin reviews1
Antisense oligonucleotides improve RNA splicing.
“Therapeutic strategies to correct splicing defects, such as antisense oligonucleotides, RNA interference, CRISPR-Cas systems, ADAR-mediated editing, and RNA aptamers, can restore a homeostatic balance of mRNA isoforms.”
Review
Loss of Splicing Homeostasis as a Hallmark of Aging
Molecular and cellular biology
Atherogenic lipoproteins and triglycerides
downin reviews1
1 study
Atherogenic lipoproteins and triglycerides
downin reviews1
Antisense oligonucleotides decrease atherogenic lipoproteins and triglycerides.
“Small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) targeting PCSK9, Lp(a), apo C-III and ANGPTL3 have shown marked efficacy in lowering atherogenic lipoproteins and triglycerides”
Review
Nucleic Acid-Based Therapies - The Next Frontier in Treating Dyslipidemias
The Canadian journal of cardiology
Inflammation
downin reviews1
1 study
Inflammation
downin reviews1
Antisense oligonucleotides decrease inflammation.
“ASOs can offer targeted intervention against key pathological mechanisms such as protein aggregation, chronic inflammation, metabolic dysfunction, and tissue fibrosis by modulating gene expression.”
Review
Antisense Oligonucleotide Therapeutics Targeting Age-Related Diseases
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Protein aggregation
downin reviews1
1 study
Protein aggregation
downin reviews1
Antisense oligonucleotides decrease protein aggregation.
“ASOs can offer targeted intervention against key pathological mechanisms such as protein aggregation, chronic inflammation, metabolic dysfunction, and tissue fibrosis by modulating gene expression.”
Review
Antisense Oligonucleotide Therapeutics Targeting Age-Related Diseases
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Epigenetic age
downin human cells1
1 study
Epigenetic age
downin human cells1
Antisense oligonucleotides decrease epigenetic age in human cells (L1 RNA depletion in progeroid patient fibroblasts).
“reversed DNA methylation age”
CellsL1 RNA depletion in progeroid patient fibroblasts
Science translational medicine
senescence-associated secretory phenotype gene expression
downin human cells1
1 study
senescence-associated secretory phenotype gene expression
downin human cells1
Antisense oligonucleotides decrease senescence-associated secretory phenotype gene expression in human cells (L1 RNA depletion in progeroid patient fibroblasts).
“counteracted the expression of senescence-associated secretory phenotype genes such as p16, p21, activating transcription factor 3 (ATF3)”
CellsL1 RNA depletion in progeroid patient fibroblasts
Science translational medicine
Histone H3 lysine 9 and lysine 27 trimethylation
upin human cells1
1 study
Histone H3 lysine 9 and lysine 27 trimethylation
upin human cells1
Antisense oligonucleotides increase histone H3 lysine 9 and lysine 27 trimethylation in human cells (L1 RNA depletion in dermal fibroblasts from patients with progeroid syndromes).
“restored heterochromatin histone 3 lysine 9 and histone 3 lysine 27 trimethylation marks”
CellsL1 RNA depletion in dermal fibroblasts from patients with progeroid syndromes
Science translational medicine
All 14Fewer
Funding
6 grants since 2019National Institute on Aging$5.9M
Targeting Brain Lipid Dysregulation in APOE4 Alzheimer's Disease with ACC Antisense Oligonucleotides
Boosting protein synthesis using antisense oligonucleotides to treat neurodegeneration
National Institute on AgingWashington University$36.6K2024–2026
Targeted Modulation of Longevity-Associated Genes Using Antisense Oligonucleotides
National Institute on AgingSaint Louis University$417K2024–2026
National Institute on AgingUniversity of California, San Diego$643K2019–2025
Splice-switching antisense oligonucleotides (SSOs) as a senomorphic intervention
How this record changed
Summary rewritten as its findings changed.
As it read before
Direct results come from one lab in mice: a preprint reports reduced pulmonary fibrosis and improved alveolar regeneration. Reviews describe lipoprotein reductions in humans. Beneficentia Stiftung Foundation is named on both findings, while National Institute on Aging funding appears in grants.
Summary written from the findings.